Advertisement

Heart Failure Reviews

, Volume 23, Issue 2, pp 191–208 | Cite as

Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review

  • Jayson R. Baman
  • Moussa Mansour
  • E. Kevin Heist
  • David T. Huang
  • Yitschak Biton
Article
  • 538 Downloads

Abstract

Atrial fibrillation is commonly coexistent with heart failure, and the management of the heart failure patient would be incomplete without an appreciation for atrial fibrillation management. There are many complications associated with oral anticoagulation in the prevention of stroke related to atrial fibrillation. In recent years, the advent of several percutaneous left atrial appendage (LAA) occlusion/closure strategies has sought to provide an alternative treatment modality. Here, we systematically review the published literature to investigate the efficacy and safety of percutaneous LAA occlusion/closure devices. We searched PubMed, EMBASE, Cochrane database of systematic reviews, and the FDA Medical Devices database. Using prespecified criteria, we identified studies of the Amplatzer Cardiac Plug (St. Jude Medical), Amplatzer Amulet (St. Jude Medical), Lariat suture delivery device (SentreHeart), and Watchman device (Boston Scientific). We analyzed 2 randomized controlled trials (RCT) and 15 non-randomized registries that satisfied the study criteria. The two RCT both studied the Watchman device versus standard warfarin therapy; the studies indicate that the Watchman may be non-inferior to warfarin. Long-term efficacy outcomes for the Watchman device are promising. Data regarding the Amplatzer Cardiac Plug, Amplatzer Amulet, and Lariat suture delivery device are limited by the paucity of RCT data. High-quality prospective research is needed to directly compare LAA occlusion/closure strategies against one another as well as versus the direct oral anticoagulation medications. Data regarding the role of LAA occlusion in the heart failure population are lacking.

Keywords

Percutaneous Left atrial appendage Atrial fibrillation Stroke Watchman 

Notes

Acknowledgments

Dr. Biton is a Mirowski Moss Career Development Awardee.

Dr. Mansour is a consultant for Boston Scientific, Abbott Laboratories, SentreHeart, Medtronic, and Biosense Webster. He has received research grants from St. Jude Medical, SentreHeart, Medtronic, and Biosense Webster.

Dr. Heist is a consultant for Boston Scientific, Biotronik, Pfizer, and Abbott Laboratories. He has received research grants from Boston Scientific and St. Jude Medical.

Supplementary material

10741_2018_9681_MOESM1_ESM.docx (11 kb)
ESM 1 (DOCX 10 kb)

References

  1. 1.
    Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112(8):1142–1147.  https://doi.org/10.1016/j.amjcard.2013.05.063 CrossRefPubMedGoogle Scholar
  2. 2.
    Sartipy U, Dahlström U, Fu M, Lund LH (2017) Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 5(8):565–574.  https://doi.org/10.1016/j.jchf.2017.05.001 CrossRefPubMedGoogle Scholar
  3. 3.
    Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL (2006) Ischemic stroke after heart failure: a community-based study. Am Heart J 152(1):102–109.  https://doi.org/10.1016/j.ahj.2005.10.018 CrossRefPubMedGoogle Scholar
  4. 4.
    Lubitz SA, Benjamin EJ, Ellinor PT (2010) Atrial fibrillation in congestive heart failure. Heart Fail Clin 6(2):187–200.  https://doi.org/10.1016/j.hfc.2009.11.001 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wolf PA, Dawber TR, Thomas HE, Kannel WB (1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28(10):973–977.  https://doi.org/10.1212/WNL.28.10.973 CrossRefPubMedGoogle Scholar
  6. 6.
    Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO (2000) Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke 31(5):1062–1068.  https://doi.org/10.1161/01.STR.31.5.1062 CrossRefPubMedGoogle Scholar
  7. 7.
    Saw J, Lempereur M (2014) Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv 7(11):1205–1220.  https://doi.org/10.1016/j.jcin.2014.05.026 CrossRefPubMedGoogle Scholar
  8. 8.
    Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15(3):244–252.  https://doi.org/10.18553/jmcp.2009.15.3.244 PubMedGoogle Scholar
  9. 9.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151.  https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMedGoogle Scholar
  10. 10.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, the ROCKET AF Steering Committee (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefPubMedGoogle Scholar
  11. 11.
    Granger CB, Alexander JH, McMurray J, Lopes RD, Hylek EM, Hanna M, al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefPubMedGoogle Scholar
  12. 12.
    Boos CJ, Nam M, Camm AJ (2014) Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 19(3):391–401.  https://doi.org/10.1007/s10741-013-9398-3 CrossRefPubMedGoogle Scholar
  13. 13.
    Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BHC (2004) The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 127(1):85–89.  https://doi.org/10.1111/j.1365-2141.2004.05162.x CrossRefPubMedGoogle Scholar
  14. 14.
    Blackshear JL, Odell JA (1996) Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61(2):755–759.  https://doi.org/10.1016/0003-4975(95)00887-X CrossRefPubMedGoogle Scholar
  15. 15.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100.  https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374(9689):534–542.  https://doi.org/10.1016/S0140-6736(09)61343-X CrossRefPubMedGoogle Scholar
  17. 17.
    Holmes DR Jr et al (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64(1):1–12.  https://doi.org/10.1016/j.jacc.2014.04.029 CrossRefPubMedGoogle Scholar
  18. 18.
    Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S (2011) Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 123(4):417–424.  https://doi.org/10.1161/CIRCULATIONAHA.110.976449 CrossRefPubMedGoogle Scholar
  19. 19.
    Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol 61(25):2551–2556.  https://doi.org/10.1016/j.jacc.2013.03.035 CrossRefPubMedGoogle Scholar
  20. 20.
    Reddy VY, Gibson DN, Kar S, O’Neill W, Doshi SK, Horton RP, Buchbinder M, Gordon NT, Holmes DR (2017) Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 69(3):253–261.  https://doi.org/10.1016/j.jacc.2016.10.010 CrossRefPubMedGoogle Scholar
  21. 21.
    Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623.  https://doi.org/10.1016/j.jacc.2015.04.025 CrossRefPubMedGoogle Scholar
  22. 22.
    Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW, EWOLUTION investigators (2016) Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37(31):2465–2474.  https://doi.org/10.1093/eurheartj/ehv730 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Bartus S, Yakubov SJ, Lee RJ (2013) Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 62(2):108–118.  https://doi.org/10.1016/j.jacc.2012.06.046 CrossRefPubMedGoogle Scholar
  24. 24.
    Price MJ, Gibson DN, Yakubov SJ, Schultz JC, di Biase L, Natale A, Burkhardt JD, Pershad A, Byrne TJ, Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T, Knight B, Lin AC, Valderrábano M (2014) Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 64(6):565–572.  https://doi.org/10.1016/j.jacc.2014.03.057 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lakkireddy D, Afzal MR, Lee RJ, Nagaraj H, Tschopp D, Gidney B, Ellis C, Altman E, Lee B, Kar S, Bhadwar N, Sanchez M, Gadiyaram V, Evonich R, Rasekh A, Cheng J, Cuoco F, Chandhok S, Gunda S, Reddy M, Atkins D, Bommana S, Cuculich P, Gibson D, Nath J, Ferrell R, Matthew E, David Wilb║║"affiliation provided but citation not provided.so i given for last author... -->er (2016) Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 13(5):1030–1036.  https://doi.org/10.1016/j.hrthm.2016.01.022 CrossRefPubMedGoogle Scholar
  26. 26.
    Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW (2016) Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 11(10):1170–1179.  https://doi.org/10.4244/EIJY15M01_06 CrossRefPubMedGoogle Scholar
  27. 27.
    Mínguez JR et al (2015) Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart 101(11):877–883.  https://doi.org/10.1136/heartjnl-2014-306332 CrossRefGoogle Scholar
  28. 28.
    Urena M, Rodés-Cabau J, Freixa X, Saw J, Webb JG, Freeman M, Horlick E, Osten M, Chan A, Marquis JF, Champagne J, Ibrahim R (2013) Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 62(2):96–102.  https://doi.org/10.1016/j.jacc.2013.02.089 CrossRefPubMedGoogle Scholar
  29. 29.
    Kleinecke C, Park JW, Gödde M, Zintl K, Schnupp S, Brachmann J (2017) Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J 24(2):131–138.  https://doi.org/10.5603/CJ.a2017.0017 CrossRefPubMedGoogle Scholar
  30. 30.
    Koskinas KC, Shakir S, Fankhauser M, Nietlispach F, Attinger-Toller A, Moschovitis A, Wenaweser P, Pilgrim T, Stortecky S, Praz F, Räber L, Windecker S, Meier B, Gloekler S (2016) Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices. JACC Cardiovasc Interv 9(13):1374–1383.  https://doi.org/10.1016/j.jcin.2016.04.019 CrossRefPubMedGoogle Scholar
  31. 31.
    Berti S, Pastormerlo LE, Rezzaghi M, Trianni G, Paradossi U, Cerone E, Ravani M, de Caterina AR, Rizza A, Palmieri C (2016) Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 102(24):1969–1973.  https://doi.org/10.1136/heartjnl-2015-309150 CrossRefPubMedGoogle Scholar
  32. 32.
    Kim JS, Lee H, Suh Y, Pak HN, Hong GR, Shim CY, Yu CW, Lee HJ, Kang WC, Shin ES, Choi RK, Kar S, Park JW, Lim DS, Jang Y (2016) Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry. Circ J 80(5):1123–1130.  https://doi.org/10.1253/circj.CJ-15-1134 CrossRefPubMedGoogle Scholar
  33. 33.
    Masoudi FA, Calkins H, Kavinsky CJ, Drozda JP Jr, Gainsley P, Slotwiner DJ, Turi ZG (2015) 2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. J Am Coll Cardiol 66(13):1497–1513.  https://doi.org/10.1016/j.jacc.2015.06.028 CrossRefPubMedGoogle Scholar
  34. 34.
    Reddy VY et al (2016) Post-FDA approval, initial US clinical experience with watchman left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll CardiolGoogle Scholar
  35. 35.
    Price MJ, Reddy VY, Valderrábano M, Halperin JL, Gibson DN, Gordon N, Huber KC, Holmes DR Jr (2015) Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv 8(15):1925–1932.  https://doi.org/10.1016/j.jcin.2015.08.035 CrossRefPubMedGoogle Scholar
  36. 36.
    Lackland DT, Elkind MS, D'Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure L, Mitchell PH, Sacco RL, Sila CA, Smith SC Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research (2012) Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43(7):1998–2027.  https://doi.org/10.1161/STR.0b013e31825bcdac CrossRefPubMedGoogle Scholar
  37. 37.
    Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr, PREVAIL and PROTECT AF Investigators (2017) 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964–2975.  https://doi.org/10.1016/j.jacc.2017.10.021 CrossRefPubMedGoogle Scholar
  38. 38.
    Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW (2016) Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 11(10):1170–1179.  https://doi.org/10.4244/EIJY15M01_06 CrossRefPubMedGoogle Scholar
  39. 39.
    Holmes DR et al (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623.  https://doi.org/10.1016/j.jacc.2015.04.025 CrossRefPubMedGoogle Scholar
  40. 40.
    Lip GY, Halperin JL (2010) Improving stroke risk stratification in atrial fibrillation. Am J Med 123(6):484–488.  https://doi.org/10.1016/j.amjmed.2009.12.013 CrossRefPubMedGoogle Scholar
  41. 41.
    Tung MK et al (2016) Retrospective cohort study examining reduced intensity and duration of anticoagulant and antiplatelet therapy following left atrial appendage occlusion with the WATCHMAN device. Heart Lung CircGoogle Scholar
  42. 42.
    Enomoto Y, Gadiyaram VK, Gianni C, Horton RP, Trivedi C, Mohanty S, di Biase L, al-Ahmad A, Burkhardt JD, Narula A, Janczyk G, Price MJ, Afzal MR, Atoui M, Earnest M, Swarup V, Doshi SK, van der Zee S, Fisher R, Lakkireddy DR, Gibson DN, Natale A, Reddy VY (2017) Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm 14(1):19–24.  https://doi.org/10.1016/j.hrthm.2016.10.020 CrossRefPubMedGoogle Scholar
  43. 43.
    Holmes DR, Reddy VY, Buchbinder M, Stein K, Elletson M, Bergmann MW, Schmidt B, Saw J (2017) The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 189:68–74.  https://doi.org/10.1016/j.ahj.2017.03.007 CrossRefPubMedGoogle Scholar
  44. 44.
    Bergmann MW et al (2017) Early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: safety and efficacy. EuroIntervention 13(7):877–884.  https://doi.org/10.4244/EIJ-D-17-00042 CrossRefPubMedGoogle Scholar
  45. 45.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1–76.  https://doi.org/10.1016/j.jacc.2014.03.022 CrossRefPubMedGoogle Scholar
  46. 46.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, de Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962.  https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMedGoogle Scholar
  47. 47.
    Seeger J, Birkemeyer R, Rottbauer W, Wöhrle J (2017) First experience with the Watchman FLX occluder for percutaneous left atrial appendage closure. Cardiovasc Revasc Med 18(7):512–516.  https://doi.org/10.1016/j.carrev.2017.04.018 CrossRefPubMedGoogle Scholar
  48. 48.
    Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus D, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE (2016) Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133(5):484–492.  https://doi.org/10.1161/CIRCULATIONAHA.115.018614 PubMedPubMedCentralGoogle Scholar
  49. 49.
    Barakat AF, Hussein AA, Saliba WI, Bassiouny M, Tarakji K, Kanj M, Jaber W, Rodriguez LL, Grimm R, Hussain MS, Russman A, Uchino K, Wisco D, Rasmussen P, Bain M, Vargo J, Zuccaro G, Gottesman D, Lindsay BD, Wazni OM (2016) Initial experience with high-risk patients excluded from clinical trials: safety of short-term anticoagulation after left atrial appendage closure device. Circ Arrhythm Electrophysiol 9(6):e004004.  https://doi.org/10.1161/CIRCEP.116.004004 CrossRefPubMedGoogle Scholar
  50. 50.
    Messori A, Trippoli S (2015) Left atrial appendage occlusion devices versus pharmacological agents for stroke prevention in atrial fibrillation. J Am Coll Cardiol 66(18):2056–2058.  https://doi.org/10.1016/j.jacc.2015.07.080 CrossRefPubMedGoogle Scholar
  51. 51.
    Amorosi SL, Armstrong S, da Deppo L, Garfield S, Stein K (2014) The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Europace 16(8):1131–1136.  https://doi.org/10.1093/europace/euu038 CrossRefPubMedGoogle Scholar
  52. 52.
    Reddy V, Akehurst R, Amorosi SL, Armstrong S, Beard S, Knight C, Taggart C, Holmes D (2015) Cost effectiveness of left atrial appendage closure versus warfarin for stroke risk reduction in non-valvular atrial fibrillation in CMS patients. Value Health 18(3):A44.  https://doi.org/10.1016/j.jval.2015.03.260 CrossRefGoogle Scholar
  53. 53.
    Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Brereton N, Hertz DS, Holmes DR Jr (2016) Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 18(7):979–986.  https://doi.org/10.1093/europace/euv412 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Micieli A, Wijeysundera HC, Qiu F, Atzema CL, Singh SM (2016) A decision analysis of percutaneous left atrial appendage occlusion relative to novel and traditional oral anticoagulation for stroke prevention in patients with new-onset atrial fibrillation. Med Decis Mak 36(3):366–374.  https://doi.org/10.1177/0272989X15593083 CrossRefGoogle Scholar
  55. 55.
    Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, al-Ahmad A, Turakhia MP (2016) Cost-effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL. Circ Arrhythm Electrophysiol 9(6):e003407.  https://doi.org/10.1161/CIRCEP.115.003407 CrossRefPubMedGoogle Scholar
  56. 56.
    Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D, PROTECT AF Steering Committee and Investigators (2014) Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312(19):1988–1998.  https://doi.org/10.1001/jama.2014.15192 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medicine, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.University of Rochester School of Medicine and DentistryRochesterUSA
  3. 3.Massachusetts General Hospital and Harvard Medical SchoolBostonUSA
  4. 4.Department of CardiologyUniversity of RochesterRochesterUSA
  5. 5.Cardiac Arrhythmia ServiceMassachusetts General HospitalBostonUSA

Personalised recommendations